US FDA Holds First Hybrid Meeting With Industry
Executive Summary
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.
You may also be interested in...
Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings
More formal meetings are available for in-person sessions with the US FDA. Also, CBER Director Peter Marks offers advice for conducting meetings, from how to do hybrid right to how to include patient groups and foreign regulators.
Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More
Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.
Supplemental Filings: Pink Sheet’s Notebook on Elon vs. FDA, Audio vs. Video, and More
Califf tweaks his misinformation stump speech, FDA adds to the Twitter COVID vaccine confusion with a tweet to Elon Musk, generic firms are schooled on the difference between a teleconference and a video conference, and other observations from Pink Sheet reporters’ notebooks.